181 related articles for article (PubMed ID: 32018283)
1. [Thromboprophylaxis in ambulatory patients with cancer].
Hart C; Heudobler D; Linnemann B
Dtsch Med Wochenschr; 2020 Feb; 145(3):130-134. PubMed ID: 32018283
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
4. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
5. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
7. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.
Bosch FTM; Mulder FI; Kamphuisen PW; Middeldorp S; Bossuyt PM; Büller HR; van Es N
Blood Adv; 2020 Oct; 4(20):5215-5225. PubMed ID: 33104795
[TBL] [Abstract][Full Text] [Related]
8. Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.
van Es N; Bleker SM; Wilts IT; Porreca E; Di Nisio M
Drugs; 2016 Mar; 76(3):331-41. PubMed ID: 26729187
[TBL] [Abstract][Full Text] [Related]
9. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
Lyman GH; Khorana AA; Falanga A; Clarke-Pearson D; Flowers C; Jahanzeb M; Kakkar A; Kuderer NM; Levine MN; Liebman H; Mendelson D; Raskob G; Somerfield MR; Thodiyil P; Trent D; Francis CW;
J Clin Oncol; 2007 Dec; 25(34):5490-505. PubMed ID: 17968019
[TBL] [Abstract][Full Text] [Related]
10. Latest advances in preventing thromboembolic disease in the ambulatory oncology patient.
Maraveyas A
Thromb Res; 2020 Jul; 191 Suppl 1():S91-S98. PubMed ID: 32736786
[TBL] [Abstract][Full Text] [Related]
11. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Key NS; Khorana AA; Kuderer NM; Bohlke K; Lee AYY; Arcelus JI; Wong SL; Balaban EP; Flowers CR; Francis CW; Gates LE; Kakkar AK; Levine MN; Liebman HA; Tempero MA; Lyman GH; Falanga A
J Clin Oncol; 2020 Feb; 38(5):496-520. PubMed ID: 31381464
[TBL] [Abstract][Full Text] [Related]
12. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
14. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
Lyman GH; Carrier M; Ay C; Di Nisio M; Hicks LK; Khorana AA; Leavitt AD; Lee AYY; Macbeth F; Morgan RL; Noble S; Sexton EA; Stenehjem D; Wiercioch W; Kahale LA; Alonso-Coello P
Blood Adv; 2021 Feb; 5(4):927-974. PubMed ID: 33570602
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
Song AB; Rosovsky RP; Connors JM; Al-Samkari H
Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
[TBL] [Abstract][Full Text] [Related]
16. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
17. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
[TBL] [Abstract][Full Text] [Related]
19. Primary venous thromboembolism prophylaxis in ambulatory cancer patients.
Aikens GB; Rivey MP; Hansen CJ
Ann Pharmacother; 2013 Feb; 47(2):198-209. PubMed ID: 23386067
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis of VTE in cancer outpatients.
Imberti D; Benedetti R
Thromb Res; 2016 Apr; 140 Suppl 1():S103-8. PubMed ID: 27067962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
